Evidence map›Paper›PMID 42834987›Full record

ArticleMaterials today. Bio2026

A core-shell microneedle patch coordinates early anti-inflammatory modulation and sustained pro-angiogenic stimulation for cardiac repair after myocardial infarction.

Yuan Luo, Rensheng Song, Yang Yang, Yi-Yun Ma, Dawei Tang, Pei Huang, Xu-Chen Liu, Qi-Hui Tang, Xiao-Fu Zhuang, Juan Zhou and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuan LuoGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Rensheng SongGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yang YangGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yi-Yun MaGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Dawei TangGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Pei HuangGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Xu-Chen LiuGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Qi-Hui TangGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Xiao-Fu ZhuangGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Juan ZhouThe Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.
Jun-Xiong LuThe Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.
Zhizhong WangGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Xue-Yan JiangGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Gen HeGuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, Department of Cardiovascular Medicine, The Fifth Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial infarction (MI) involves a temporally evolving pathological cascade, in which acute NLRP3 inflammasome-mediated inflammation and insufficient reparative angiogenesis sequentially contribute to adverse ventricular remodeling. However, most current therapies lack the spatiotemporal control needed to match these evolving therapeutic demands. Here, we developed a core-shell microneedle (MN)-based epicardial patch for spatiotemporally programmed MI treatment through sequential delivery of the NLRP3 inhibitor MCC950 and basic fibroblast growth factor (bFGF). The rapidly hydrating methacrylated hyaluronic acid (HAMA) shell enabled early release of MCC950 to suppress acute inflammatory injury, whereas the chitosan-based core and backing layer provided sustained bFGF release to support later angiogenesis. The resulting HAMA/CS MN patch exhibited a well-defined core-shell architecture, suitable mechanical strength, excellent cytocompatibility, and differentiated release behavior.

Indexed as

AngiogenesisCardiac repairCore-shell microneedle patchMyocardial infarctionNLRP3 inflammasomeSequential drug delivery

Identifiers

PMID42834987
PMCPMC13634988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.